# Clinical Safety Documentation Standards

## Executive Summary

This document establishes comprehensive clinical safety standards for healthcare technology products, including hazard analysis, risk management, failure mode analysis, and post-market surveillance procedures. All healthcare systems must adhere to IEC 14971 risk management principles and FDA patient safety requirements.

---

## 1. Hazard Analysis Framework

### 1.1 Hazard Identification Process

**Definitions:**
- **Hazard**: A potential source of harm
- **Risk**: The combination of probability and severity of harm
- **Harm**: Physical injury or damage to health

#### Hazard Identification Methods

**1. Systematic Review (FMEA-driven)**
```
For each software module/function:
  1. What can go wrong?
  2. How can it go wrong?
  3. What is the failure mode?
  4. What is the effect on patient/clinician?
  5. What is the severity if it occurs?
  6. How likely is it to occur?
```

**2. Stakeholder Interviews**
- Clinical staff (physicians, nurses, pharmacists)
- IT operations staff
- Patients and families
- Regulatory specialists
- Device manufacturers

**3. Literature Review**
- FDA Medical Device Reporting (MDR) database
- Adverse event databases (MAUDE, OpenMEPS)
- Published incident reports
- Risk assessments from similar products

**4. Fault Tree Analysis**
```
HAZARD: Patient receives wrong medication

    ┌─────────────────────────────────────────┐
    │ Patient Receives Wrong Medication      │
    └────────────┬────────────────────────────┘
                 │
         ┌───────┴────────┬──────────────┐
         │                │              │
    Wrong patient    Wrong drug       Wrong dose
    selected         prescribed       entered
         │                │              │
    ┌────┴─────┐      ┌────┴────┐   ┌───┴────┐
    │           │      │         │   │        │
  Search  UI    │    Drug     Typo  Calculation
  returns  error │   lookup    in   error
  multiple      │    failed   order
  matches       │
```

### 1.2 Hazard Analysis Table

```
HAZARD ANALYSIS FOR EHR MEDICATION ORDERING MODULE
═════════════════════════════════════════════════════════════════

ID  HAZARD             CAUSE              EFFECT ON        SEVERITY
                                         PATIENT/PROCESS
───────────────────────────────────────────────────────────────────
H1  Medication         System crash       Patient doesn't  MAJOR
    order not sent     before order       receive needed   (E)
    to pharmacy        transmitted        medication

H2  Drug inter-        Drug interaction   Adverse drug     CRITICAL
    action not         checking fails     event (ADE)      (F)
    detected           (DB not updated)

H3  Allergy            Patient allergy    Anaphylaxis,    CRITICAL
    contraindication   not displayed      death            (F)
    missed             in UI

H4  Duplicate          Clinician          Over-medication, MAJOR
    medication order   clicks submit      hospitalization  (E)
    created            multiple times

H5  Wrong patient      Patient search     Medication to    CRITICAL
    selected           returns multiple   wrong patient,   (F)
                       matches            potential death

H6  Incorrect dose     Manual calculation Over/under-dose, MAJOR
    entered            error              organ damage     (E)

H7  System unavailable Server maintenance Delays in        MODERATE
    during peak hours  unscheduled        ordering,        (D)
                                          workflow impact

SEVERITY LEVELS:
A = Negligible (no harm, minor inconvenience)
B = Minor (temporary harm, minor treatment)
C = Significant (serious harm, hospitalization)
D = Major (extended hospitalization, permanent harm risk)
E = Critical (death or permanent harm possible)
F = Catastrophic (death or permanent harm likely)
```

### 1.3 FMEA (Failure Mode and Effects Analysis)

**Complete FMEA Table:**

```
FMEA: EHR MEDICATION ORDERING SYSTEM
═════════════════════════════════════════════════════════════════════

Item: Medication Order Entry
Sub-Function: Drug Selection

ID  FAILURE    EFFECTS        SEVERITY  CAUSE         CURRENT      RPN
    MODE                       (S)                     CONTROLS     (S×O×D)
─────────────────────────────────────────────────────────────────────
1   No drug    Wrong patient  9         Drug master   2-factor     162
    available  receives drug  (critical) not updated; auth for
    in system  or delayed     (9×3×6)   searching wrong order
                treatment              patient name  verification

2   Duplicate  Patient        8         User clicks   Disable
    order                     receives  submit       submit after  96
                              2x dose;  button       click; 3-sec
    (major)   organ damage   multiple  (8×2×6)      timeout
                              times;    on network

3   Drug-drug Adverse event,  10        Drug inter-   Monthly DB    120
    inter-    hospitalization (catastrophic) action DB  updates;
    action               (10×2×6)      outdated or  2-factor
    missed                            not queried   verification

4   Over-dose Renal failure,  8         Dose calc    Weight-based   96
              death          (major)    error or    dose calc
                             (8×3×4)    manual      tool; dose
                                       entry error  range check

5   Wrong     Death or       10         Allergy not  Auto-display   150
    patient  serious        (catastrophic) in EHR;  allergies
    selected reaction       (10×3×5)   UI doesn't   on order
                                       show clearly screen; alert

RISK PRIORITY NUMBER (RPN) = Severity × Occurrence × Detectability

Scoring:
  Severity (1-10): How serious if it happens?
  Occurrence (1-10): How likely is it to happen?
  Detectability (1-10): How likely to catch before patient harm?

ACTION ITEMS (RPN > 100):
→ Item 1: Redesign drug search to prevent wrong patient
→ Item 3: Update drug interaction DB monthly (automated)
→ Item 5: Major UI redesign for allergy highlighting
```

---

## 2. Risk Management Plan (IEC 14971)

### 2.1 Risk Management Process Overview

```
RISK MANAGEMENT LIFECYCLE
═════════════════════════════════════════════════════════════════

PHASE 1: RISK ANALYSIS
  ├─ Identify hazards (see 1.1-1.3 above)
  ├─ Classify risks (severity, probability)
  └─ Create risk register

PHASE 2: RISK EVALUATION
  ├─ Assess individual risks
  ├─ Prioritize by RPN (Risk Priority Number)
  └─ Determine acceptability criteria

PHASE 3: RISK CONTROL (MITIGATION)
  ├─ Design controls
  ├─ Implement controls
  └─ Verify effectiveness

PHASE 4: RESIDUAL RISK EVALUATION
  ├─ Assess remaining risk after controls
  ├─ Determine if acceptable
  └─ Plan further mitigation if needed

PHASE 5: RISK MANAGEMENT REVIEW
  ├─ Evaluate overall product risk
  ├─ Post-market surveillance planning
  └─ Document risk acceptance

PHASE 6: POST-MARKET SURVEILLANCE
  ├─ Monitor for new hazards
  ├─ Collect adverse events
  ├─ Analyze trends
  └─ Implement corrective actions
```

### 2.2 Risk Evaluation Matrix

```
RISK EVALUATION AND CONTROL STRATEGY

RISK MATRIX (Severity vs. Probability):
                      PROBABILITY
                  Low    Medium   High    Very High
              ┌────────────────────────────────────┐
          E   │ Medium  HIGH    CRITICAL CRITICAL  │
          (5) │        │        │        │        │
          D   │ Low   Medium   HIGH    CRITICAL   │
      SEVERITY │        │        │        │        │
      (1-10)C   │ Low   Low    Medium   HIGH     │
              │ (3) │        │        │        │
          B   │ Low   Low    Low     Medium    │
              │ (2) │        │        │        │
          A   │ Low   Low    Low     Low       │
              │ (1) │        │        │        │
              └────────────────────────────────────┘

COLOR CODING:
┌──────────────────────────────────────────────────┐
│ GREEN (Low Risk): Acceptable, routine monitoring│
│ YELLOW (Medium Risk): Control required          │
│ ORANGE (High Risk): Significant control needed  │
│ RED (Critical): Must eliminate or control strictly
└──────────────────────────────────────────────────┘

RISK ACCEPTABILITY CRITERIA:
✓ GREEN:     No additional controls needed
✓ YELLOW:    Implement design controls (testing, UI redesign)
⚠ ORANGE:    Implement multiple controls + validation testing
✗ RED:       May not proceed without eliminating hazard or
             comprehensive mitigation + clinical validation
```

### 2.3 Risk Control Measures

**Hierarchy of Controls:**

```
1. ELIMINATION (Remove hazard entirely)
   Example: Remove feature that has uncontrollable risk
   → Simplify medication search: Remove free-text search,
     use autocomplete dropdown only (prevents wrong patient)

2. SUBSTITUTION (Replace with lower-risk alternative)
   Example: Manual dose calculation → Automated dose calculator
   Benefits: Eliminates human calculation error

3. ENGINEERING CONTROLS (Built-in safeguards)
   Example:
   - Drug interaction database with real-time checking
   - Mandatory allergy verification before order submission
   - Weight-based dose calculation with range checking
   - Confirmation screen showing patient name, drug, dose
   - Duplicate order detection (within 5 minutes)

4. ADMINISTRATIVE CONTROLS (Procedures, training)
   Example:
   - Clinician training on safe ordering practices
   - Standardized order entry procedures
   - Verification by pharmacist before dispensing
   - Super-user approval for critical medications

5. PERSONAL PROTECTIVE EQUIPMENT (PPE - Least effective)
   Not applicable to software, but represents the least
   reliable control method in healthcare

RECOMMENDED APPROACH:
Use multiple layers of controls. Example for medication ordering:

   Layer 1: ENGINEERING - Autocomplete drug search
          → Prevents wrong patient, prevents typos

   Layer 2: ENGINEERING - Drug interaction checking
          → Prevents harmful drug combinations

   Layer 3: ENGINEERING - Allergy display
          → Prevents allergic reactions

   Layer 4: ENGINEERING - Confirmation screen
          → Allows clinician to verify before submission

   Layer 5: ADMINISTRATIVE - Pharmacist verification
          → Final human check before dispensing

   Layer 6: ADMINISTRATIVE - Patient education
          → Patient verifies medications received
```

### 2.4 Risk Control Verification

```
VERIFICATION CHECKLIST FOR EACH CONTROL MEASURE

CONTROL: Drug Interaction Checking Database

Requirement:
  "System shall check all new medication orders against
   FDA drug interaction database and alert clinician if
   moderate or severe interactions detected"

Verification Method:
  ✓ Code review (check for correct DB query)
  ✓ Automated testing (test cases for known interactions)
  ✓ Manual testing (clinical staff testing)
  ✓ Performance testing (response time <500ms)

Test Cases Required:
  TC-01: No interaction between Aspirin + Lisinopril
         → System allows order (no alert)

  TC-02: Moderate interaction between Warfarin + Aspirin
         → System alerts "Increased bleeding risk"

  TC-03: Critical interaction between Warfarin + NSAIDs
         → System prevents order, shows strong alert

  TC-04: Unknown drug in database
         → System handles gracefully, logs warning

Pass Criteria:
  ✓ 100% of known interactions detected
  ✓ <5% false positive rate (acceptable per FDA)
  ✓ Response time <500ms
  ✓ No system crashes on large datasets

Sign-Off:
  Quality Assurance: _____________ Date: _______
  Clinical Advisor: _____________ Date: _______
  Regulatory Affairs: __________ Date: _______
```

---

## 3. Testing and Validation for Safety

### 3.1 Clinical Safety Test Plan

```
CLINICAL SAFETY TEST PLAN
═════════════════════════════════════════════════════════════════

OBJECTIVE:
Verify that all identified hazards are controlled to acceptable
levels and that the system is safe for clinical use.

TEST APPROACH:
┌─────────────────┬──────────────────────────────────────┐
│ Test Type       │ Scope                               │
├─────────────────┼──────────────────────────────────────┤
│ Unit Testing    │ Individual functions (code level)   │
│ Integration     │ Component interactions              │
│ System Testing  │ Entire medication ordering workflow│
│ Clinical UAT    │ Real workflows with clinical staff  │
│ Safety Testing  │ Stress tests, boundary testing     │
└─────────────────┴──────────────────────────────────────┘

CRITICAL TEST SCENARIOS:

Scenario 1: Patient Safety - Wrong Patient Selection
  Precondition: Multiple patients with similar names in system
  Test: User searches "John Smith" (returns 5 results)
  Action: Select correct patient from list
  Verification: Verify order placed for correct patient
  Acceptance: 100% accuracy required

Scenario 2: Drug Interaction Alert
  Precondition: Patient on Warfarin (anticoagulant)
  Test: Attempt to order Ibuprofen (NSAID)
  Action: Submit order
  Verification: System alerts "HIGH RISK: Increased bleeding"
  Acceptance: Alert must appear before order submission

Scenario 3: Allergy Override Protection
  Precondition: Patient with documented Penicillin allergy
  Test: Attempt to order Amoxicillin (penicillin-based)
  Action: Submit order
  Verification: System prevents order and shows alert
  Acceptance: Order cannot be submitted despite override attempt

Scenario 4: Dose Range Checking
  Precondition: Patient weighs 65 kg
  Test: Attempt to order Metoprolol 500 mg (normal: 25-200 mg)
  Action: Submit order
  Verification: System alerts "DOSE EXCEEDS RANGE"
  Acceptance: Order cannot be submitted without pharmacist
              approval and documented justification
```

### 3.2 Stress and Boundary Testing

```
STRESS TESTING FOR SAFETY-CRITICAL FUNCTIONS

Test Case: High Volume Order Processing
  Load: 1000 concurrent medication orders
  Duration: 2 hours continuous
  Measurement: Response time, error rate, data integrity
  Pass Criteria:
    - Response time <2 seconds (95th percentile)
    - No drug interactions missed
    - No duplicate orders created
    - No data loss or corruption
    - All orders logged in audit trail

Test Case: Database Query Under Load
  Load: 500 drug interaction checks simultaneously
  Expected: Rapid response, accurate results
  Failure Mode: Timeout or slow response could delay care
  Pass Criteria:
    - 100% queries return results <500ms
    - <0.1% timeout rate acceptable

Test Case: System Recovery from Failure
  Scenario: Database connection lost during order submission
  Action: Restart database
  Verification:
    - No lost orders
    - No duplicate orders created
    - Audit trail complete
    - System recovers without manual intervention

BOUNDARY TESTING:

Input Boundaries:
  ✓ Minimum dose: 0.001 mg (valid for some drugs)
  ✓ Maximum dose: Test up to 10,000 mg
  ✓ Patient age: 0-120 years
  ✓ Patient weight: 0.5 kg - 300 kg
  ✓ Drug name: Test with special characters, accents
  ✓ Dose frequency: Test all valid frequencies

Data Type Boundaries:
  ✓ Numeric fields: Negative numbers, decimals, overflow
  ✓ Text fields: Empty strings, null values, max length
  ✓ Date fields: Past dates, future dates, invalid formats
  ✓ Boolean fields: True/false/null/undefined
```

---

## 4. Failure Mode Effects and Criticality Analysis (FMECA)

### 4.1 FMECA Process

```
FMECA EXAMPLE: PATIENT AUTHENTICATION MODULE

Function: Authenticate clinician to access EHR

┌─────────────────────────────────────────────────────────────┐
│ FAILURE MODE: System accepts invalid password               │
├─────────────────────────────────────────────────────────────┤
│ EFFECT: Unauthorized person accesses patient data          │
│ SEVERITY: Critical (data breach, HIPAA violation)          │
│ OCCURRENCE: Low (strong encryption controls)               │
│ DETECTABILITY: High (authentication testing)               │
│ RPN: 8 × 2 × 2 = 32                                        │
│                                                             │
│ CAUSE: Hash algorithm weakness or implementation bug       │
│                                                             │
│ EXISTING CONTROLS:                                          │
│ ✓ FIPS 140-2 encryption                                   │
│ ✓ Annual security audit                                    │
│ ✓ Password complexity requirements                         │
│ ✓ Failed login tracking                                    │
│                                                             │
│ RISK LEVEL: MEDIUM (RPN=32, but Critical severity)        │
│                                                             │
│ RECOMMENDED ACTIONS:                                        │
│ 1. Implement multi-factor authentication (2FA/MFA)        │
│ 2. Use NIST-approved hashing (bcrypt/Argon2)             │
│ 3. Security code review by third party                     │
│ 4. Annual penetration testing                              │
│ 5. Implement rate limiting (5 attempts/15 min)            │
│                                                             │
│ RESIDUAL RISK AFTER CONTROLS:                              │
│ ✓ RPN reduced to 8 × 1 × 1 = 8 (Acceptable)              │
│ ✓ Severity remains Critical but occurrence/detection ↓     │
└─────────────────────────────────────────────────────────────┘
```

### 4.2 Criticality Assessment

```
CRITICALITY MATRIX FOR SOFTWARE FAILURES

CRITICALITY CLASS A: CATASTROPHIC
  Definition: Failure causes death or permanent serious injury
  Examples:
  - Medication overdose (100x normal dose)
  - Wrong patient receives surgery medication
  - Cardiac monitor alarm fails to alert
  Action: Zero tolerance, must be eliminated or triple-redundancy

CRITICALITY CLASS B: MAJOR
  Definition: Failure causes significant injury requiring hospitalization
  Examples:
  - Medication interaction not detected
  - Allergy data not displayed
  - Dose calculation off by 10x
  Action: Multiple controls required, strict testing

CRITICALITY CLASS C: SERIOUS
  Definition: Failure causes minor injury or significant disruption
  Examples:
  - Medication ordering delayed
  - Report not generated
  - Non-critical data corruption
  Action: Standard controls, normal testing

CRITICALITY CLASS D: MINOR
  Definition: Failure causes minor inconvenience
  Examples:
  - Display formatting issue
  - Non-critical report unavailable
  - UI responsiveness slow
  Action: Basic controls, routine monitoring

CLASSIFICATION FOR MEDICATION ORDERING SYSTEM:

CATASTROPHIC (Class A):
  □ Patient receives >2x intended dose
  □ Wrong patient receives medication
  □ Life-threatening drug interaction missed
  □ Documented allergy contraindication bypassed

MAJOR (Class B):
  □ Non-life-threatening drug interaction missed
  □ Moderate-severity allergy not detected
  □ Order sent to wrong pharmacy (caught before dispensing)
  □ Duplicate order (caught by pharmacy)

SERIOUS (Class C):
  □ Order processing delayed
  □ Minor drug incompatibility missed
  □ Report formatting error

MINOR (Class D):
  □ Cosmetic UI issues
  □ Non-critical data display error
```

---

## 5. Adverse Event Monitoring and Reporting

### 5.1 Medical Device Reporting (MDR) System

**FDA Requirement**: Report serious adverse events within 30 days

#### Event Classification

```
REPORTABLE ADVERSE EVENTS:

1. DEATH
   Definition: Any death reasonably related to the device
   Reporting Timeline: Within 30 days
   Example: Patient receives wrong medication due to system error,
            leading to fatal outcome

2. SERIOUS INJURY
   Definition: Injury that results in:
   - Permanent impairment of body function
   - Permanent damage to body structure
   - Necessity for medical/surgical intervention

   Examples:
   - Medication omission due to system failure requiring ICU admission
   - Drug interaction not detected, causing organ damage

3. MALFUNCTION
   Definition: Device fails to perform function, could cause
                adverse event if it reoccurs

   Examples:
   - System crash during critical medication order
   - Database corruption affecting patient record integrity
   - Failed drug interaction check (caught in testing)

NON-REPORTABLE EVENTS:
  ✗ User error (clinician enters wrong dose - not system's fault)
  ✗ System downtime for scheduled maintenance
  ✗ Slow performance (unless causes missed diagnosis timing)
  ✗ Minor data display issues (no clinical impact)
```

#### MDR Form Submission

```
FDA FORM 3500A - MEDICAL DEVICE REPORT

1. DEVICE IDENTIFICATION:
   Manufacturer: Example Health Systems Inc.
   Device Name: EHR Medication Ordering Module
   Model Number: v2.1.3
   Serial Number: SOFT-123456

2. EVENT DESCRIPTION:
   Date of Event: January 15, 2025
   Date Reported: January 20, 2025 (within 30 days)

   Description of what happened:
   "Patient was ordered Metformin 500 mg BID (twice daily).
   Due to system software glitch in dose frequency dropdown,
   order was sent to pharmacy as Metformin 500 mg QID (4x daily).
   Pharmacy caught error before dispensing. Patient received
   appropriate dose. No patient harm."

3. PATIENT INFORMATION:
   Patient ID: DE-IDENTIFIED per HIPAA
   Age: 65
   Sex: M

4. HEALTH OUTCOME:
   □ Death
   □ Serious injury
   ✓ Malfunction - No patient harm (caught in process)
   □ Other adverse event

5. DEVICE MALFUNCTION:
   Describe malfunction:
   "Medication frequency dropdown selected wrong value
   (index +1 error in code). Dose frequency 'BID' was
   converted to 'QID' in pharmacy transmission."

6. ROOT CAUSE:
   "Off-by-one error in dose frequency array mapping
   (line 342 in medication_order_processor.py).
   Array[2] should map to frequency 'BID' but mapped to 'QID'.
   User input was correct; software error in transmission."

7. CORRECTIVE ACTIONS TAKEN:
   - Immediate: Hotfix deployed, array indices corrected
   - Short-term: All affected orders reviewed (5 patients, all OK)
   - Long-term: Unit test added for all 10 frequency options
                Code review process updated to catch array errors

8. MANUFACTURER CONTACT:
   Name: Dr. James Chen, Chief Medical Officer
   Phone: 555-XXX-XXXX
   Email: jchen@ehrsystems.com
```

### 5.2 Post-Market Surveillance Plan

```
POST-MARKET SURVEILLANCE PLAN
EHR MEDICATION ORDERING SYSTEM v2.0

OBJECTIVE:
Collect and analyze adverse event data to ensure continued safety
and identify potential new hazards.

SURVEILLANCE METHODS:

1. PASSIVE SURVEILLANCE (Reactive)
   - Clinician incident reporting system
   - Patient complaint log
   - Help desk ticket analysis
   - Peer institution sharing network

   Frequency: Continuous
   Analysis: Monthly review
   Reporting: Quarterly to quality committee

2. ACTIVE SURVEILLANCE (Proactive)
   - Monthly review of specific high-risk functions
     • Medication interaction checks
     • Dose range verification
     • Allergy detection
   - Sampling: 100 random orders/month
   - Method: Retrospective chart review by pharmacist

   Frequency: Monthly audits
   Metrics: Error rate, near-miss rate
   Threshold: >0.5% error rate triggers investigation

3. DATA ANALYSIS & TRENDING
   - Events tracked by type:
     • Wrong patient selection
     • Drug interaction misses
     • Allergy missed
     • Dose errors
     • System downtime

   - Statistical tracking:
     Events per 10,000 orders
     Trend analysis (↑ or ↓)
     Comparison to benchmark (similar EHR systems)

4. INCIDENT INVESTIGATION
   When event occurs:

   Step 1: Triage (within 24 hours)
     - Severity assessment
     - Patient outcome
     - Root cause obvious?

   Step 2: Investigation (within 5 days)
     - Root cause analysis (5-Why method)
     - Determine if system-related
     - Check if isolated or systematic

   Step 3: Corrective Action (within 30 days if serious)
     - Fix design/workflow
     - Update training
     - Communicate to users
     - Test change
     - Redeploy

5. REPORTING & ESCALATION
   Event Rate: <0.1% (target)

   Escalation Triggers:
   ✓ Any patient death (→ MDR within 30 days)
   ✓ Cluster of similar events (3+ in 30 days)
   ✓ Unknown new hazard identified
   ✓ Regulatory notification received
   ✓ System downtime >4 hours

   Escalation Path:
   Clinical → QA Manager → CISO → CIO → CMO → FDA (if required)

6. COMMUNICATION & UPDATES
   - Monthly: Safety report to quality committee
   - Quarterly: Summary to clinical staff
   - Annual: Comprehensive post-market review
   - As needed: Urgent communications for critical issues

EXAMPLE METRICS DASHBOARD:

Month: January 2025
Total Orders: 10,542
Adverse Events: 2 (0.02% - Target: <0.1%)

Events by Type:
  Duplicate Orders: 1 (0.009%) ✓ Acceptable
  Drug Interaction Missed: 0 ✓ Zero target
  Allergy Missed: 0 ✓ Zero target
  Wrong Patient: 0 ✓ Zero target
  Dose Range Violation: 1 (0.009%) ✓ Acceptable

Root Causes:
  1. Duplicate: User clicked submit twice (UI/UX issue, not system)
  2. Dose: Manual calculation override by senior physician

Corrective Actions This Month:
  □ Reduce submit button double-click interval (UI redesign)
  □ Reinforce training on automatic dose calculator

Next Steps:
  → Monitor for duplicate orders in February
  → Verify dose override changes in March
```

---

## 6. Clinical Safety Requirements Specification

### 6.1 Safety Requirements Document

```
CLINICAL SAFETY REQUIREMENTS SPECIFICATION
EHR MEDICATION ORDERING MODULE

CSR-001: Medication Safety - Patient Identification
  Requirement: System shall uniquely identify patient for each
               medication order and prevent orders to wrong patient
  Acceptance Criteria:
    • Patient ID verified in 3 locations (patient select → order screen → confirm)
    • Patient name displayed prominently (>14pt, bold)
    • Search results show DOB and MRN to distinguish similar names
    • System prevents order submission without explicit patient confirmation
  Priority: CRITICAL (Severity F)
  Test Method: Clinical UAT, error testing
  Compliance: FDA SaMD guidance, IEC 62304

CSR-002: Drug Interaction Detection
  Requirement: System shall check all medication orders against
               FDA-approved drug interaction database and alert
               for moderate or severe interactions
  Acceptance Criteria:
    • Drug database updated monthly with FDA changes
    • Check occurs before order submission
    • Alert severity indicated (moderate/severe/critical)
    • Interaction rationale provided to clinician
    • Order cannot proceed without acknowledgment
  Priority: CRITICAL (Severity E)
  Test Method: Test cases for known interactions, quarterly audit
  Compliance: JCAHO standards, FDA guidance

CSR-003: Allergy Information Display
  Requirement: System shall display all documented allergies
               prominently on medication order screen
  Acceptance Criteria:
    • Allergies displayed above fold, >16pt font
    • Color-coded (Red background)
    • Includes reaction severity (mild/moderate/severe/anaphylaxis)
    • Checked for cross-reactivity (e.g., penicillin ← amoxicillin)
    • System prevents contraindicated medication order
  Priority: CRITICAL (Severity E)
  Test Method: Clinical UAT, automated testing
  Compliance: Patient safety standards

CSR-004: Dose Range Checking
  Requirement: System shall verify medication doses are within
               recommended range based on patient characteristics
  Acceptance Criteria:
    • Weight-based dosing calculations performed automatically
    • Renal function (eGFR) used for dose adjustment when applicable
    • Age-based dosing for pediatrics
    • System alerts if dose outside recommended range
    • Pharmacist review required for out-of-range doses
    • Documented justification required for override
  Priority: HIGH (Severity D)
  Test Method: Integration testing, clinical validation
  Compliance: JCAHO, pharmacy standards

CSR-005: Audit Trail Completeness
  Requirement: System shall maintain complete audit trail of all
               medication order transactions per 21 CFR Part 11
  Acceptance Criteria:
    • Every order logged: submit, modify, cancel, verify
    • Timestamp to second, timezone included
    • User ID and role recorded
    • Changes show before/after values
    • Log cannot be modified or deleted (append-only)
    • Log retained for minimum 6 years
  Priority: CRITICAL (Severity F - Regulatory)
  Test Method: Compliance audit, automated testing
  Compliance: FDA 21 CFR Part 11, HIPAA

CSR-006: System Uptime & Performance
  Requirement: System shall maintain availability for medication
               ordering during all patient care hours
  Acceptance Criteria:
    • Uptime: 99.5% during 6am-10pm (peak hours)
    • Response time: <2 seconds (95th percentile)
    • Database query time: <500ms
    • No order loss during system restart
    • Automatic failover to backup system (<1 min)
  Priority: HIGH (Severity D - Care disruption)
  Test Method: Load testing, monitoring, incident response drills
  Compliance: Clinical operations standards
```

---

## 7. Patient Safety Case Files

### 7.1 Safety Case Structure

```
SAFETY CASE: EHR Medication Ordering System v2.0

OBJECTIVE CLAIM:
"The EHR Medication Ordering Module is acceptably safe for
clinical use, with identified hazards controlled to acceptable
levels of risk."

EVIDENCE STRUCTURE:

├── SAFETY ARGUMENT
│   └── Goal: System is safe for medication ordering
│       ├── Sub-goal 1: Critical hazards are eliminated
│       │   └── Evidence: Hazard analysis document (Appendix A)
│       │   └── Evidence: Control verification tests (Appendix B)
│       │
│       ├── Sub-goal 2: Residual risks are acceptable
│       │   └── Evidence: Risk assessment matrix (Section 2.2)
│       │   └── Evidence: FMEA with RPN scores (Section 4.1)
│       │   └── Evidence: Clinical validation tests (Section 3)
│       │
│       ├── Sub-goal 3: Controls verified and validated
│       │   └── Evidence: Test results (Appendix C)
│       │   └── Evidence: Clinical UAT sign-off (Appendix D)
│       │   └── Evidence: Security audit report (Appendix E)
│       │
│       └── Sub-goal 4: Post-market monitoring will catch
│           new hazards
│           └── Evidence: Surveillance plan (Section 5.2)
│           └── Evidence: Incident response procedures
│
├── SUPPORTING EVIDENCE
│   ├── Hazard Analysis (FMEA table)
│   ├── Risk Management Plan
│   ├── Design Specification
│   ├── Test Reports
│   ├── Clinical Validation Report
│   ├── Security Assessment
│   ├── Regulatory Compliance Checklist
│   └── Post-Market Surveillance Plan
│
└── ASSUMPTIONS & LIMITATIONS
    ├── Assumes: Clinicians receive appropriate training
    ├── Assumes: System properly maintained and updated
    ├── Limitation: Cannot eliminate all user errors
    ├── Limitation: Dependent on accurate drug database updates
    └── Limitation: Requires pharmacist oversight for verification
```

### 7.2 Safety Case Approval

```
SAFETY CASE APPROVAL SIGN-OFF

Product: EHR Medication Ordering Module v2.0
Date: January 15, 2025

I have reviewed the complete safety case including:
☑ Hazard analysis and FMEA
☑ Risk management plan and controls
☑ Design specification and architecture
☑ Test plans and results
☑ Clinical validation report
☑ Security assessment
☑ Post-market surveillance plan

Based on the evidence presented, I conclude:

☑ Critical hazards are adequately controlled
☑ Residual risks are acceptable for clinical use
☑ Design controls are effective and verified
☑ System meets FDA safety requirements
☑ System meets HIPAA security requirements
☑ Clinical staff can safely use this system

APPROVAL:

Chief Medical Officer:        _________________ Date: _______
(Responsible for patient safety and clinical validation)

Chief Technology Officer:     _________________ Date: _______
(Responsible for system design and security)

Quality Assurance Manager:    _________________ Date: _______
(Responsible for testing and compliance)

Regulatory Affairs Manager:   _________________ Date: _______
(Responsible for regulatory compliance)

Hospital Administrator:       _________________ Date: _______
(Final approval authority)

APPROVAL STATUS: ✓ APPROVED FOR CLINICAL USE
Date Approved: January 15, 2025
Conditions:
  1. Pharmacist verification required for all orders
  2. Post-market surveillance monitoring ongoing
  3. Annual safety review required
  4. Immediate reporting of any adverse events to quality committee
```

---

## 8. Compliance Checklist

### Clinical Safety
- [ ] Hazard analysis (FMEA) completed
- [ ] Risk management plan documented
- [ ] Risk controls identified and verified
- [ ] Residual risk acceptable
- [ ] Clinical safety test plan executed
- [ ] Clinical staff validation testing completed
- [ ] Safety case documented
- [ ] Post-market surveillance plan created

### FDA Requirements
- [ ] Hazard analysis documented
- [ ] Risk management per IEC 14971
- [ ] Design controls implemented
- [ ] Software V&V testing completed
- [ ] Post-market surveillance plan
- [ ] MDR procedures established

### Quality Assurance
- [ ] Test cases documented
- [ ] Test coverage ≥90% critical paths
- [ ] All test cases executed and passed
- [ ] FMEA RPN scores acceptable
- [ ] Control verification completed
- [ ] Clinical UAT sign-off obtained

### Regulatory Compliance
- [ ] HIPAA security controls verified
- [ ] 21 CFR Part 11 audit trails implemented
- [ ] FDA device classification correct
- [ ] Predicate device identified (if Class II)
- [ ] Substantial equivalence documented
- [ ] Post-market data collection plan

---

## 9. References and Resources

### Regulatory Standards
- IEC 14971: Risk Management for Medical Devices
- IEC 62304: Medical Device Software Lifecycle Processes
- FDA: "Software as a Medical Device (SaMD): Key Definitions"
- 21 CFR Part 11: Electronic Records; Electronic Signatures

### Clinical Safety Resources
- Patient Safety Indicators: Agency for Healthcare Research & Quality
- Safer Healthcare Now: Canadian toolkit
- The Joint Commission (JCAHO): Patient Safety Standards
- ISMP: Institute for Safe Medication Practices

### Industry Examples
- NHS England: Safety Assurance of Health IT Systems
- VA: Veterans Affairs Medical Device Software Safety
- HIMSS: Healthcare IT Safety Framework

---

**Version**: 1.0
**Last Updated**: 2025-11-19
**Compliance Level**: FDA IEC 14971, 21 CFR Part 11, HIPAA, JCAHO
